Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q4 2023 call → NOWe need to determine if management describes that successive engagements of the same kind are coming in at progressively larger size. The question asks about a specific phenomenon: the unit size of repeatable business escalating. We need to look for management's own words conveying a comparison against the company's own recent past, that it's already real and recurring, and that it's early. Let's scan the transcript. The call covers Alibaba's earnings. Management discusses various segments: Taobao/Tmall, International Commerce, Cloud, etc. We need to find any mention of deals, orders, contracts, projects, customers, sites, or programs getting individually bigger. Looking at the transcript, there is discussion about growth, but is there any mention of the size of individual engagements increasing? For example, in cloud, they talk about revenue growth, but not about the size of contracts. In international commerce, they talk about growth, but not about deal size. In Taobao, they talk about user growth and GMV, but not about individual order size. The question specifically asks about "successive engagements of the same kind" coming in at "progressively larger size." That would be like average order value increasing, or new customers starting at larger scale, or contracts getting bigger. I don't see any such statement. There is mention of "Choice" service in AliExpress, but that's about a new service, not about size escalation. There is mention of "Tongyi Qianwen" model, but that's about a product launch. Management does talk about "high-quality growth" and "focus on high-quality growth" but that's not about unit size. Also, there is discussion about restructuring and spin-offs, but that's not about deal size. I see no mention of the size of orders, contracts, or projects increasing. The only thing close is maybe in cloud, they talk about "hybrid cloud projects" but they mention delays, not size. Thus, the answer is NO. Management does not describe that successive engagements are coming in at progressively larger size. They talk about growth in revenue, users, GMV, but not about the unit size of individual deals escalating. So answer: NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.